EDI – Kosten der Gewalt in Paarbeziehungen

 EDI – Kosten der Gewalt in Paarbeziehungen Bern, 19.11.2013 – Kosten in der Höhe von mindestens 164 Millionen Franken jährlich entstehen der Gesellschaft durch Gewalt in Paarbeziehungen. Ein im Auftrag des Eidgenössischen Büros für die Gleichstellung von Frau und Mann EBG erarbeiteter Forschungsbericht weist erstmals systematisch die Folgekosten von Gewalt in Paarbeziehungen aus und zeigt auf, in welchen Kostenbereichen diese anfallen.Eidgenössisches Departement des Innern

Roche presents lampalizumab biomarker data from phase II study in advanced form of dry macular degeneration

a  • MAHALO phase II data previously showed a reduction in disease progression in patients with geographic atrophy, the advanced form of dry age-related macular degeneration (AMD)• Strongest treatment effect was observed in patients positive for the Complement Factor I (CFI) genetic biomarker• Roche will continue to investigate the biomarker strategy to identify people who would benefit most from treatment with lampalizumabRoche (SIX: RO, ROG; OTCQX: RHHBY) today announced additional encouraging phase II results with lampalizumab from the MAHALO study in patients with geographic atrophy (GA). GA is characterised by the irreversible loss of retinal tissue in the macula that results in permanent blind spots in a patient’s central vision. In a sub-population of GA patients positive for the Complement Factor I (CFI) biomarker, who received monthly lampalizumab, data from an exploratory analysis show a 44 percent decrease (p<0.005) in the rate of disease progression at 18 months. When lampalizumab was administered every other month, the rate of disease progression was decreased by 18 percent (p=0.23) in the biomarker defined sub-group of patients. No unexpected or unmanageable serious adverse events were detected in the MAHALO study. These data were presented at the 2013 Retina Subspecialty Day Session of the Annual Meeting at the American Academy of Ophthalmology in New Orleans, Louisiana, USA.“The phase II results are good news for patients with geographic atrophy, a major vision-impairing disease where there is currently no treatment available,” said Richard Scheller, Ph.D., Head of Genentech Research and Early Development. “These preliminary biomarker data show the CFI biomarker could help identify patients most likely to respond to treatment with lampalizumab.”AMD has a strong genetic component with genetic factors accounting for more than 50 percent of the risk for the disease.(1) Genetic polymorphisms in the complement pathway have been implicated in the development of AMD including GA. In the MAHALO study, 57 percent of genotype samples collected from 93 patients were positive for the CFI biomarker. Although the phase II study was relatively small, these results suggest the CFI biomarker is both prognostic for GA area progression and predictive for lampalizumab treatment response. Only MAHALO patients that were positive for the CFI biomarker showed a treatment effect with lampalizumab.AMD is a leading cause of blindness in adults over 55 years of age in the developed world. There are two forms of AMD, wet AMD and dry AMD. GA, the advanced form of dry AMD, affects more than 8 million people worldwide.(2) While therapies have become available for wet AMD, currently there are no approved treatments for people with GA.About the MAHALO studyThe phase II trial was a multi-centre, randomised, single-masked, controlled study of the safety, tolerability and evidence of activity of lampalizumab in patients with GA associated with AMD. Study participants received lampalizumab injections in one eye either monthly or every other month for 18 months. The primary endpoint was change of GA area from baseline to month 18 compared with control, as assessed with fundus autofluorescence (FAF). Four genetic biomarkers were examined in MAHALO, including complement factor H (CFH), C3, C2/CFB and CFI. In the MAHALO study, most patients had a background of CFH and C2/CFB.Lampalizumab showed a 20.4 percent reduction rate in the area of geographic atrophy at 18 months that was statistically significant (p=0.1170) per pre-specified protocol criteria in patients with this advanced form of dry AMD. The efficacy assessed by FAF was observed in those receiving monthly injections beginning at month six and maintained through month 18. A secondary endpoint of change in GA area from baseline to month 18 was assessed by colour fundus photographs and these results confirmed the FAF primary endpoint outcome.In a sub-population of GA patients treated monthly with lampalizumab that were positive for the CFI exploratory biomarker, the GA progression rate was decreased by 44 percent at 18 months (p<0.005). Safety outcome measures included incidence and severity of ocular and non-ocular (systemic) adverse events (AE). Intraocular inflammation AE rates and intraocular pressure elevation AE rates were consistent with Lucentis rates for these AEs in wet AMD. The most frequently reported AEs in the study eye were associated with the injection procedure. There were no intraocular infections, no unexpected or unmanageable serious AEs, no death or ocular serious AEs suspected to be caused by study drug and no ocular serious AEs in study eye leading to treatment discontinuation.About lampalizumabLampalizumab is being investigated to determine its effect on the progression of GA associated with advanced dry AMD.  The molecule is an antigen-binding fragment (Fab) of a humanised, monoclonal antibody directed against complement factor D. Complement factor D is a rate-limiting enzyme involved in the activation of the alternative complement pathway (ACP). The ACP is a component of the immune system’s natural defence against infections. Genetic polymorphisms as well as hyperactivity of the ACP have been implicated in the development of AMD including GA.About geographic atrophy (GA)GA is an advanced form of AMD and is a progressive, irreversible and blinding disease. GA is responsible for irreversible severe vision loss in approximately 20 percent of all patients with AMD.(3-4) Visual impairment associated with GA tends to affect both eyes in many individuals. GA patients report visual problems with reading, recognising faces, and activities in low illumination. GA represents a significant unmet medical need as there are no approved treatments for this condition.About Roche in ophthalmologyRoche’s ophthalmology medicines include Lucentis (ranibizumab injection), which is indicated in the United States for the treatment of wet age-related macular degeneration (wet AMD), macular edema following retinal vein occlusion (RVO) and diabetic macular edema (DME).Lucentis was discovered by Genentech and continues to be developed by Genentech and Novartis for diseases or disorders of the eye. Genentech retains commercial rights in the U.S. and Novartis has exclusive commercial rights for the rest of the world.About RocheHeadquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, infectious diseases, ophthalmology, inflammation, metabolism and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2012 Roche had over 82,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 45.5 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.All trademarks used or mentioned in this release are protected by law.References:1. Seddon JM, Ajani UA, Mitchell BD. Familial aggregation of age related maculopathy. Am J Ophthalmol 1997; 123: 199-206.2. Rudnicka, A. et al,”Age and Gender Variations in Age-related Macular Degeneration Prevalence in Populations of European Ancestry: A Meta-analysis,”Ophthalmology, 2012; 119:571–580.3. Clemons TE, Milton RC, Klein R, Seddon JM, Ferris FL III; Age-Related Eye Disease Study Research Group. Risk factors for the incidence of Advanced Age-Related Macular Degeneration in the Age-Related Eye Disease Study (AREDS) AREDS report no. 19. Ophthalmology 2005;112:533–9.4. Zarbin MA, Rosenfeld PJ. Pathway-based therapies for age-related macular degeneration: an integrated survey of emerging treatment alternatives. Retina 2010;30:1350–67.With best regards,Roche Investor RelationsDr. Karl MahlerPhone: +41 61 68-78503e-mail: karl.mahler@roche.comDr. Sabine BorngräberPhone: +41 61 68-88027e-mail: sabine.borngraeber@roche.comLuís Correia Ph.D.Phone: +41 61 68-75284e-mail: luis.correia@roche.comTamer Farhan Ph.D.Phone: +41 61 68-82552e-mail: tamer.farhan@roche.comDr. Nina MojasPhone: +41 61 68-71300e-mail: nina.mojas@roche.comElhan Webb, CFAPhone: +41 61 68-89630e-mail: elhan.webb@roche.comInvestor Relations North AmericaThomas Kudsk LarsenPhone: +1 650 467 2016e-mail: larsen.thomas@gene.comNina GoworekPhone: +1 650 467 8737e-mail: goworek.nina@gene.comEkaterine Kortkhonjia Ph.D.Phone: +1 650 467 5873e-mail: kortkhonjia.ekaterine@gene.com

Gurit to present its product offering for superior FST behaviour and excellent surface finishing for parts and panels at Railway and Mass Transit Interiors Expo 2013, Germany

a With over 30 years of experience as a prime composite materials supplier and engineering partner to a broad array of industrial markets including high-end applications such as today’s most advanced passenger aircraft or weight and performance optimised composite wind turbine blades, Gurit also understands the most pressing needs of the rail market. Key parameters of passengers’ safety are the fire, smoke and toxicity (FST) performance of the materials chosen. All these aspects can be optimised by using state-of-the-art composite materials that are ideally suited to manufacture weight-optimised laminate structures, sandwich or crushed-core components like e.g. fairings, windows, ceilings and floor panels that exceed the customers’ performance criteria and the most stringent safety requirements. Exhibiting on stand 4170, Gurit will be showcasing its manufacturing expertise to the rail market, which enables products like prepregs, structural core materials and adhesives to be tailored to customers’ exact requirements. Gurit’s prepregs combine advanced resin formulations with various kinds of reinforcements, hybrids or unidirectional (UD) tapes. Two of these products being highlighted at the show are:PH 840 PH 840 is a low volatile phenolic and low moisture content prepreg system which ensures the production of parts and panels with excellent surface and provides excellent FST properties. Gurit's PH 840 is one of the best commercially available phenolic system thanks to both its process ability properties and the good quality surface that can be achieved on final parts. SPRINT™ ST 70 or ST 70 FR (fire retardant) Gurit’s innovative SPRINT™ product range uses a high flow, low tack epoxy prepreg ideally suited to the manufacture of exterior structures in combination with Corecell™ foam core. The major benefit of SPRINT™ is that it enables all of the air to be removed from the laminate prior to fibre wet out and resin cure. Gurit’s sales and technical staff will be available on stand 4170 to discuss the range of advanced composite materials available for the Rail and Mass Transit markets.

Swiss Re General news release: Swiss Re unveils new brand strategy and modernized logo as it celebrates 150 year anniversary

The day of its official anniversary of 150 years, leading re / insurance Swiss Re unveils a new brand strategy and a modernized logo. The new brand promise "We are smarter together" aims to support Swiss Re ambition for growth companies and differentiation on the market.

Group CEO Michel M. Liès said: "for the last 150 years, it was Swiss Re company to allow people to turn the pioneer of the ideas in reality, or get back on the right track when things go wrong. We had our anniversary at the opportunity to review our brand positioning and launch a new brand promise: 'We are smarter together' is public statement of Swiss Re which highlight the spirit of partnership of our knowledge-based society, committed to helping customers succeed. Our mutual success will actually address the persistent phenomenon of underinsurance in many regions of our planet and that always specific protection gaps of the face, companies and also countries. »

Launch of the new brand strategy and the logo modernized Swiss Re
Revised Swiss Re branding has been defined after extensive consultation with internal and external stakeholders. An economic and strategic asset important, it must be protected and improved continuously. Swiss Re is strongly associated with attributes such as the expertise, global, integrity, strong financial and heritage. The Executive Committee of the Group decided to build on existing strengths, but also slightly reposition the company in the future, in order to present it as more emotional, focusing on the benefits and collaborative. This program aims to enable the company to stand farther out on the market.

Part of the change is the Swiss Re logo modernization to make it a more powerful and more distinct symbol on markets around the world. While the so-called pillars be maintained for stability, the new roundel expresses customer orientation and worldliness. The Board of Directors and the Group Executive Committee also approved a strategy of 'one-mark' for the whole of the group with its three business units.

Publication of the book on the history of Swiss Re
Swiss Re also published a book on the history of the company and the industry. Produced in German and English, she traces the evolution of a small start-up company in a small office in the old town of Zürich in a giant industry with more than 11,000 employees in more than 60 locations. Richly illustrated with dozens of photographs and reprints, the publication is divided into three parts: it opens an overview of the development of the insurance sector, describes the journey of the reinsurance industry and then ends in the history of Swiss Re itself. The book was written by Peter Borscheid, Professor Emeritus of social and economic history at the University of Marburg (insurance), David Gugerli, Professor of history of technology at ETH Zurich (reinsurance) and Tobias Straumann, lecturer at the research centre for economic and social history at the University of Zurich (Swiss Re). It is edited by Harold James, Professor of history at Princeton University, USA and has a foreword by Walter Kielholz, Chairman of the Swiss Re Group.

"As a reinsurer, Swiss Re had to internationalise its activities from the outset in order to diversify its portfolio of risks. While most of the major disasters that struck in the past have left traces in the books of the company: the San Francisco of 1906 earthquake, sinking hurricanes Titanic, the great depression, Andrew and Katrina and 9/11. "At the same time, the company has always demonstrated a deep attachment to the Switzerland and benefited from the forces and the values that go with the brand Switzerland", explains Tobias Straumann.

Contact:
Rolf Tanner
Head of Media Relations
media_relations@SwissRe.com
Phone + 41 43 285 7171

For more information about Swiss Re please visit our website www.swissre.com.

Nestlé joins alliance for responsible plant-based plastics

a Nestlé has announced that it will work in partnership with the World Wildlife Fund (WWF) and seven consumer firms to encourage the responsible development of bioplastics, derived from plant materials.Along with Nestlé, the Bioplastic Feedstock Alliance (BFA) will include key fast-moving consumer goods firms The Coca-Cola Company, Danone, Ford, H.J. Heinz Company, Nike, P&G, and Unilever.As consumers across the world seek sustainable alternatives to petroleum-based products, the alliance will aim to guide the responsible selection and harvesting of agricultural materials - such as sugar cane, corn, bulrush, and switchgrass - used to make bioplastics.Real alternatives"Joining the alliance means we will be able to help build a more sustainable future for the bioplastics industry whilst addressing issues such as land use, food security and biodiversity," said Nestlé's Global Research and Development Sustainability Manager, Anne Roulin.BFA intends to bring together leading experts from industry, academia and civil society to develop and support informed science, collaboration, education, and innovation to help guide the evaluation and sustainable development of materials that can be made into bioplastics.Critical for conservation"Ensuring that our crops are used responsibly to create bioplastics is a critical conservation goal, especially as the global population is expected to grow rapidly through 2050," said Erin Simon, of WWF.Already, bioplastics made from sugar cane and other plant-based materials are used in Nestlé's product portfolio. Since early 2012, for example, several sizes of VITTEL bottled water have been packaged in an innovative PET bottle made from 30% plant-based material.Nestlé is particularly interested in second generation bioplastics, made, for example, from the by-products of forestry, agriculture or the food chain - such as molasses or cane residue - or non-food sources such as algae, cellulose and waste products.Related information:The Bioplastics Feedstock Alliancehttp://www.bioplasticfeedstockalliance.org/Nestlé and Environmental Sustainability: Packaginghttp://www.nestle.com/csv/environmental-sustainability/packagingNestlé and Creating Shared Valuehttp://www.nestle.com/CSVVittel Waterhttp://www.vittel.com/fr/index.htmRead more about Nestlé and bioplastics:Nestlé sees bioplastics as the future of packaginghttp://www.nestle.com/media/newsandfeatures/nestle-sees-bioplastics-as-future-of-packagingNestlé Waters and bioplasticshttp://www.nestle-waters.com/environment/bottled-water-packaging/pet-bottles-bio-plasticsNestlé launches bioplastic caps for milk brands in Brazilhttp://www.nestle.com/Media/NewsAndFeatures/Nestle-launches-bioplastic-caps-for-milk-brands-in-BrazilMedia enquiries Tel: +41 21 924 2200 Email: Nestlé Corporate Media Relations

Schweiter verkauft Liegenschaft in La Chaux-de-Fonds

a Horgen, 15. November, 2013 - Schweiter Technologies veräussert die nicht betriebsnotwendige Liegenschaft in La Chaux-de-Fonds an Procimmo Swiss Commercial Fund.Der Verkaufspreis beträgt CHF 18.3 Mio - mit dem Verkauf erzielt Schweiter Technologies einen Buchgewinn im tiefen einstelligen Millionenbereich.Procimmo Swiss Commercial Fund ist ein auf kommerzielle Bauten spezialisierter Immobilienfonds und ist an der Schweizer Börse SIX Swiss Exchange kotiert.Für weitere Informationen:Martin Klöti, Head of Management ServicesTel. +41 44 718 33 03, Fax +41 44 718 34 51, martin.kloeti@schweiter.comSchweiter Technologies AG, Neugasse 10, CH - 8810 Horgen, SwitzerlandTelefon +41 44 718 33 03 Fax +41 44 718 34 51 info@schweiter.comhttp://www.schweiter.com/Die Medienmitteilung ist auf folgendem Link als PDF abrufbar:

Rock in the new subcutaneous formulation RoACTEMRA receives positive opinion from the CHMP in Europe moderate to severe rheumatoid arthritis

AppId is over the quota
© 2000-2013 Armando Guglielmetti

Désolé, que je ne pouvais pas lire le contenu fromt cette page.